Related Experiment Video
Updated: Oct 9, 2026

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
Published on: December 2, 2016
Correction of hypertensive cardiac remodelling: comparison of different antihypertensive therapies
V A Almazov1, E V Shlyakhto, A O Konrady
1Faculty Therapy Dept., St. Petersburg Pavlov State Medical University, 6/8 Lev Tołstoy str., St. Petersburg 197089, Russia.
Insights
Long-term use of various antihypertensive drugs effectively reduces left ventricular hypertrophy (LVH) and improves diastolic function. This cardiac remodeling benefit occurs independently of blood pressure reduction, with no single drug showing superiority.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Essential hypertension is a significant risk factor for cardiovascular complications, including left ventricular hypertrophy (LVH).
- LVH is associated with impaired diastolic function and increased risk of heart failure.
- Understanding the impact of different antihypertensive drug classes on cardiac structure and function is crucial for effective patient management.
Purpose of the Study:
- To compare the effects of long-term treatment with nifedipine, atenolol, losartan, and perindopril on LVH and diastolic function in hypertensive patients.
- To investigate whether the observed changes in cardiac remodeling are related to blood pressure reduction.
Main Methods:
- A six-month prospective study involving 60 middle-aged patients with mild to moderate essential hypertension.
- Patients received one of four antihypertensive drugs: nifedipine-retard, atenolol, losartan potassium, or perindopril.
- Echocardiography was used to assess left ventricular mass index (LVMI), relative wall thickness (RWT), and diastolic function parameters (E/A ratio, IVRT).
Main Results:
- All drug treatments led to a significant decrease in LVMI and RWT, indicating reversal of LVH.
- The reduction in LVH was more pronounced in patients with higher baseline LVMI and was independent of blood pressure reduction.
- Diastolic function parameters improved, suggesting enhanced cardiac relaxation and filling.
Conclusions:
- Long-term treatment with nifedipine, atenolol, losartan, and perindopril improves cardiac structure and diastolic function in hypertensive patients.
- The beneficial effects on cardiac remodeling are independent of the drugs' blood pressure-lowering effects.
- No specific drug demonstrated superiority in improving cardiac remodeling, suggesting a class effect for these antihypertensives.
Abstract:
The aim of the study was to compare the effects of long-term treatment with different types of antihypertensive drugs on left ventricular hypertrophy (LVH) and diastolic function in patients with essential hypertension. We examined 60 patients with mild to moderate hypertension from 35 to 55 years old (middle age 44.3 +/- 2.3 yrs) having no concomitant diseases. Patients were treated for six months with different types of antihypertensive drugs: 21 patient received nifedipine-retard 40 mg/day, 20--atenolol 100 mg/day, 10--losartan potassium 100 mg/day, 9--perindopril 4 mg/day. Cardiac structure and function was studied by echocardiography. For the left ventricle (LV) the diastolic mass normalised for body surface area (LVMI), the ratio of the early and atrial mitral inflow velocities (E/A), isovolumetric relaxation time (IVRT), relative wall thickness (RWT) were measured. After six months of treatment LVMI decreased by 9% in nifedipine group (P < 0.01), by 10.5% in atenolol group (P < 0.01), by 12% in losartan group (P < 0.01) and by 8.2% in perindopril group (NS). RWT decreased in all groups, while diastolic dimension index remained unchanged. The reversal of LVH was not related to blood pressure reduction. It was more significant in patients with initially higher values of LVMI. Antihypertensive effects of the drugs were comparable. Long-term treatment with all types of selected drugs improves cardiac structure and function independently of their antihypertensive action. Our data suggest that on the basis of the influence on cardiac remodelling no preference for any studied drug can be discerned. The work had the following source of support: the atenolol (Falitonsin) and nifedipine-retard (Corinfar-retard) were provided by the AWD Company (Germany), losartan potassium has been provided by Merck Sharp & Dohme Company and perindopril (Prestarium) by the Servier Group.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Hypertension IV: Drug Therapy and Lifestyle Modifications
Heart Failure V: Medical Management
Cardiomyopathy V: Interprofessional Care
Heart Failure II: Pathophysiology
Heart Failure Drugs: Diuretics